Liposomes as Carriers of Proteins: Possible Medical Applications

  • Gregory Gregoriadis


The use of proteins in therapeutic and preventive medicine is often associated with a number of difficulties. In inherited metabolic disorders, for instance, replacement therapy with enzymes foreign to the body can be immunogenic and promote hypersensitivity reactions. In addition, access of such enzymes to the target is often poor either because of inactivation by extracellular or intracellular agents or because of target inaccessibility. Some enzymes, such as glycohydrolases potentially useful in the treatment of lysosomal storage diseases, have been shown to act on non-target substrates located on cell surfaces or circulating glycoproteins, thus upsetting normal metabolism (1). In other instances administration of a protein through a particular route which would have been beneficial to the patient, is impossible because of the protein’s properties. Thus, oral treatment of diabetes and of other peptide hormone deficiencies is prevented by the hormone’s vulnerability in the gut.


Lysosomal Storage Disease Dipalmitoyl Phosphatidylcholine Empty Liposome Aqueous Space Dimyristoyl Phosphatidylcholine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    GREGORIADIS, G., PUTMAN, D., LOUIS, L. & NEERUNJUN, D. Biochem. J. 140:323,1974.Google Scholar
  2. 2.
    GREGORIADIS, G.New Engt. J. Med.295:704 & 765, 19 76.Google Scholar
  3. 3.
    GREGORIADIS, G.Meth. in Enzymovogy 44:218, 1976.CrossRefGoogle Scholar
  4. 4.
    GREGORIADIS, 44:698, 1976.CrossRefGoogle Scholar
  5. 5.
    BLACK, C.D.V. & GREGORIADIS,G. Biochem. Soc. Titans. 4: 253, 1976.Google Scholar
  6. 6.
    WISSE, E., GREGORIADIS, G. & DAEMS, W.Th. in “The Reticuloendothelial System in Health and Disease: Functions and characteristics,” ( S.M. Reichard, M.R. Escobar & H. Friedman, eds.), Plenum Publishing Corporation, New York, 1976, p. 237.Google Scholar
  7. 7.
    PAPAHADJOPOULOS, D., POSTE, G. & MAYHEW, E.Biochom. biophys.Acta 363: 404, 1974.CrossRefGoogle Scholar
  8. 8.
    GREGORIADIS, G. & NEERUNJUN, E.D.Biochem. Biophys. Reh.Comm. 65: 537, 1975.CrossRefGoogle Scholar
  9. 9.
    GREGORIADIS, G., NEERUNJUN, D.E. & HUNT, R. Life. Sciences 21: 357, 1977.Google Scholar
  10. 10.
    BRAIDMAN, I.P. & GREGORIADIS, G.Biochem.J. 164: 439, 1977.Google Scholar
  11. 11.
    BELCHETZ, P.E., BRAIDMAN, I.P., CRAWLEY, J.C.W. & GREGORIADIS, G. Lancet.ii: 116, 1977.Google Scholar
  12. 12.
    OP DEN KAMP, J.A.F., KAUERZ, M.T. & VAN DEENEN, L.L.Biochim. Biophys.Acta 406:169,1975.CrossRefGoogle Scholar
  13. 13.
    DAPERGOLAS, G. & GREGORIADIS, G.Biochem. Soc.Tians. 5: 1383, 1977.Google Scholar
  14. 14.
    DAPERGOLAS, G. & GREGORIADIS, G. Lancet ii: 824, 1976.Google Scholar
  15. 15.
    ALLISON, A.C. & GREGORIADIS, G. in “Recent Results in Cancer Research,” ( G. Mathe, I. Florentin & M.-C. Simmler, eds.), Springer Verlag, Heildenberg, 1976, p. 58.Google Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • Gregory Gregoriadis
    • 1
  1. 1.Division of Clinical InvestigationClinical Research Center HarrowUK

Personalised recommendations